Does Rallies show 13F holders for RNAZ?

Yes. Rallies tracks hedge fund and 13F ownership data for RNAZ, including fund names, share counts, latest tracked quarter, and position changes when available.

Is RNAZ research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RNAZ. It does not provide personalized investment advice.

RNAZ (TransCode Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

TransCode Therapeutics, Inc. Common Stock (RNAZ) is a publicly traded Healthcare sector company. As of May 21, 2026, RNAZ trades at $6.35 with a market cap of $5.66M and a P/E ratio of -0.12. RNAZ moved +0.00% today. Year to date, RNAZ is -17.43%; over the trailing twelve months it is -25.12%. Its 52-week range spans $5.56 to $739.20. Rallies surfaces RNAZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns RNAZ stock?

Hedge funds tracked by Rallies that own RNAZ include Citadel Advisors and Two Sigma. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for TransCode Therapeutics, Inc. Common Stock.

RNAZ Key Metrics

Key financial metrics for RNAZ
Metric	Value
Price	$6.35
Market Cap	$5.66M
P/E Ratio	-0.12
EPS	$-52.59
Dividend Yield	0.00%
52-Week High	$739.20
52-Week Low	$5.56
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-34.66M
Gross Margin	0.00%

Top Hedge Funds Holding RNAZ

Citadel Advisors holds 25.51K shares of RNAZ, changed -90.95% as of Jun 30, 2024.
Two Sigma holds 12.85K shares of RNAZ, changed -41.51% as of Jun 30, 2024.

Latest RNAZ News

TransCode Names Dr. Anna Moore SAB Chair, Signs MSU Research Deal — Apr 27, 2026

Recent RNAZ Insider Trades

Fitzgerald Thomas A bought 49.35K (~$25.17K) on Sep 28, 2023.
Dudley Robert Michael bought 98.00K (~$49.98K) on Sep 28, 2023.
Dudley Robert Michael bought 12.00K (~$31.82K) on Jun 21, 2023.

RNAZ Analyst Consensus

RNAZ analyst coverage data. Average price target: $0.00.

Common questions about RNAZ

Who owns RNAZ stock?: Hedge funds tracked by Rallies that own RNAZ include Citadel Advisors and Two Sigma. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for TransCode Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for RNAZ?: Yes. Rallies tracks hedge fund and 13F ownership data for RNAZ, including fund names, share counts, latest tracked quarter, and position changes when available.
Is RNAZ research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RNAZ. It does not provide personalized investment advice.